Understanding how certain proteins affect inflammation in Down syndrome
Mediator kinases as interferon antagonists in Down Syndrome
This study is looking at how certain proteins in the body affect inflammation in people with Down syndrome, with the hope of finding new ways to help reduce ongoing inflammation and improve health for those individuals.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado NIH-funded |
| Lab location | 1 site (Boulder, UNITED STATES) |
| Project ID | NIH-10892908 on NIH RePORTER |
What this research studies
This research investigates the roles of specific proteins called Mediator kinases (CDK8 and CDK19) in regulating inflammation in individuals with Down syndrome. By examining how these proteins contribute to excessive immune signaling, the study aims to identify potential therapeutic targets that could help reduce chronic inflammation associated with Down syndrome. The research employs advanced techniques such as transcriptomics and metabolomics to analyze cellular responses and mechanisms in Down syndrome patients. Ultimately, the goal is to develop strategies to mitigate the inflammatory effects that contribute to various health issues in this population.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with Down syndrome who may experience chronic inflammation and its related health complications.
Not a fit: Patients without Down syndrome or those not experiencing significant inflammatory issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that alleviate chronic inflammation and improve health outcomes for individuals with Down syndrome.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other inflammatory conditions, suggesting potential for success in this novel approach.
Where this research is happening
Boulder, UNITED STATES
- University of Colorado — Boulder, United States (Active)
Researchers
- Principal investigator: Taatjes, Dylan J — University of Colorado
- Study coordinator: Taatjes, Dylan J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.